Risk factors for severe outcomes for COVID-19 patients hospitalised in Switzerland during the first pandemic wave, February to August 2020: prospective observational cohort study
As clinical signs of COVID-19 differ widely among individuals, from mild to severe, the definition of risk groups has important consequences for recommendations to the public, control measures and patient management, and needs to be reviewed regularly.
The aim of this study was to explore risk factors for in-hospital mortality and intensive care unit (ICU) admission for hospitalised COVID-19 patients during the first epidemic wave in Switzerland, as an example of a country that coped well during the first wave of the pandemic.
This study included all (n = 3590) adult polymerase chain reaction (PCR)-confirmed hospitalised patients in 17 hospitals from the hospital-based surveillance of COVID-19 (CH-Sur) by 1 September 2020. We calculated univariable and multivariable (adjusted) (1) proportional hazards (Fine and Gray) survival regression models and (2) logistic regression models for in-hospital mortality and admission to ICU, to evaluate the most common comorbidities as potential risk factors.
RESULTS AND DISCUSSION
We found that old age was the strongest factor for in-hospital mortality after having adjusted for gender and the considered comorbidities (hazard ratio [HR] 2.46, 95% confidence interval [CI] 2.33−2.59 and HR 5.6 95% CI 5.23−6 for ages 65 and 80 years, respectively). In addition, male gender remained an important risk factor in the multivariable models (HR 1.47, 95% CI 1.41−1.53). Of all comorbidities, renal disease, oncological pathologies, chronic respiratory disease, cardiovascular disease (but not hypertension) and dementia were also risk factors for in-hospital mortality. With respect to ICU admission risk, the pattern was different, as patients with higher chances of survival might have been admitted more often to ICU. Male gender (OR 1.91, 95% CI 1.58−2.31), hypertension (OR 1.3, 95% CI 1.07−1.59) and age 55–79 years (OR 1.15, 95% CI 1.06−1.26) are risk factors for ICU admission. Patients aged 80+ years, as well as patients with dementia or with liver disease were admitted less often to ICU.
We conclude that increasing age is the most important risk factor for in-hospital mortality of hospitalised COVID-19 patients in Switzerland, along with male gender and followed by the presence of comorbidities such as renal diseases, chronic respiratory or cardiovascular disease, oncological malignancies and dementia. Male gender, hypertension and age between 55 and 79 years are, however, risk factors for ICU admission. Mortality and ICU admission need to be considered as separate outcomes when investigating risk factors for pandemic control measures and for hospital resources planning.
- Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568–76. doi:.https://doi.org/10.1002/jmv.25748
- Gupta RK, Marks M, Samuels THA, Luintel A, Rampling T, Chowdhury H, et al.; UCLH COVID-19 Reporting Group. Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. Eur Respir J. 2020;56(6):2003498. doi:.https://doi.org/10.1183/13993003.03498-2020
- Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al.; ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369(March):m1985. doi:.https://doi.org/10.1136/bmj.m1985
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6. doi:.https://doi.org/10.1038/s41586-020-2521-4
- Swiss Academy Of Medical Sciences. COVID-19 pandemic: triage for intensive-care treatment under resource scarcity (3rd, updated version). Swiss Med Wkly. 2020;150:w20401. doi:.https://doi.org/10.4414/smw.2020.20401
- Thiabaud A, Iten A, Balmelli C, Senn L, Troillet N, Widmer A, et al. Cohort profile: SARS-CoV-2/COVID-19 hospitalised patients in Switzerland. Swiss Med Wkly. 2021;151:w20475. doi:.https://doi.org/10.4414/smw.2021.20475
- van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67. doi:.https://doi.org/10.18637/jss.v045.i03
- Shepherd BE, Rebeiro PF ; Caribbean, Central and South America network for HIV epidemiology. Assessing and interpreting the association between continuous covariates and outcomes in observational studies of HIV using splines. J Acquir Immune Defic Syndr. 2017;74(3):e60–3. doi:.https://doi.org/10.1097/QAI.0000000000001221
- Harrell FE. Regression Modeling Strategies [Internet]. Springer Series in Statistics. 2015. Available from: https://link.springer.com/content/pdf/10.1007/978-3-319-19425-7.pdf
- Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94(446):496–509. doi:.https://doi.org/10.1080/01621459.1999.10474144
- Gray RJ. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat. 1988;16(3):1141–54. doi:.https://doi.org/10.1214/aos/1176350951
- Therneau T. A package for survival analysis in R [Internet]. 2020. Available from: https://cran.r-project.org/web/packages/survival/vignettes/survival.pdf
- Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389–430. doi:.https://doi.org/10.1002/sim.2712
- Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11(1):5749. doi:.https://doi.org/10.1038/s41467-020-19478-2
- Smith LH, VanderWeele TJ. Bounding Bias Due to Selection. Epidemiology. 2019;30(4):509–16. doi:.https://doi.org/10.1097/EDE.0000000000001032
- Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113:154378. doi:.https://doi.org/10.1016/j.metabol.2020.154378
- Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age. ACS Chem Neurosci. 2020;11(11):1555–62. doi:.https://doi.org/10.1021/acschemneuro.0c00210
- Ciaglia E, Vecchione C, Puca AA. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children. Front Pediatr. 2020;8(April):206. doi:.https://doi.org/10.3389/fped.2020.00206
- Vellas C, Delobel P, de Souto Barreto P, Izopet J. COVID-19, Virology and Geroscience: A Perspective. J Nutr Health Aging. 2020;24(7):685–91. doi:.https://doi.org/10.1007/s12603-020-1416-2
- Pawelec G, Bronikowski A, Cunnane SC, Ferrucci L, Franceschi C, Fülöp T, et al. The conundrum of human immune system “senescence”. Mech Ageing Dev. 2020;192:111357. doi:.https://doi.org/10.1016/j.mad.2020.111357
- Galloway JB, Norton S, Barker RD, Brookes A, Carey I, Clarke BD, et al. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. J Infect. 2020;81(2):282–8. doi:.https://doi.org/10.1016/j.jinf.2020.05.064
- Huang H, Cai S, Li Y, Li Y, Fan Y, Li L, et al. Prognostic factors for COVID-19 pneumonia progression to severe 2 symptom based on the earlier clinical features: a retrospective analysis. medRxiv. 2020;7:557453. doi:.https://doi.org/10.3389/fmed.2020.557453
- Swiss Federal Office for Public Health. Kategorien besonders gefährdeter Personen [Internet]. 2020. Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/besonders-gefaehrdete-menschen.html